WallStSmart

CME Group Inc (CME)vsTransUnion (TRU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CME Group Inc generates 42% more annual revenue ($6.51B vs $4.58B). CME leads profitability with a 62.6% profit margin vs 10.0%. TRU appears more attractively valued with a PEG of 1.14. TRU earns a higher WallStSmart Score of 66/100 (B-).

CME

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 7.5Value: 7.3Quality: 5.5
Piotroski: 1/9

TRU

Strong Buy

66

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 10.0Quality: 7.5
Piotroski: 6/9Altman Z: 1.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CMEUndervalued (+43.8%)

Margin of Safety

+43.8%

Fair Value

$522.76

Current Price

$293.93

$228.83 discount

UndervaluedFair: $522.76Overvalued
TRUUndervalued (+33.9%)

Margin of Safety

+33.9%

Fair Value

$108.58

Current Price

$67.72

$40.86 discount

UndervaluedFair: $108.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CME6 strengths · Avg: 9.0/10
Profit MarginProfitability
62.6%10/10

Keeps 63 of every $100 in revenue as profit

Operating MarginProfitability
63.8%10/10

Strong operational efficiency at 63.8%

Market CapQuality
$105.67B9/10

Large-cap with strong market position

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
35.0%8/10

Earnings expanding 35.0% YoY

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

TRU2 strengths · Avg: 9.0/10
EPS GrowthGrowth
52.8%10/10

Earnings expanding 52.8% YoY

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

CME3 concerns · Avg: 3.0/10
P/E RatioValuation
26.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
5.842/10

Expensive relative to growth rate

TRU3 concerns · Avg: 3.7/10
P/E RatioValuation
29.6x4/10

Moderate valuation

Altman Z-ScoreHealth
1.524/10

Distress zone — elevated risk

Debt/EquityHealth
1.153/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CME

The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 62.6% and operating margin at 63.8%.

Bull Case : TRU

The strongest argument for TRU centers on EPS Growth, Price/Book. Revenue growth of 13.0% demonstrates continued momentum. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : CME

The primary concerns for CME are P/E Ratio, Piotroski F-Score, PEG Ratio.

Bear Case : TRU

The primary concerns for TRU are P/E Ratio, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CME profiles as a mature stock while TRU is a value play — different risk/reward profiles.

TRU carries more volatility with a beta of 1.70 — expect wider price swings.

TRU is growing revenue faster at 13.0% — sustainability is the question.

CME generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

TRU scores higher overall (66/100 vs 63/100) and 13.0% revenue growth. CME offers better value entry with a 43.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CME Group Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.

Visit Website →

TransUnion

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

TransUnion offers risk and information solutions. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?